All In Biotech

Drug Trial Radar · NCT03303521

A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients.

A Phase 3b, Multicenter, Prospective, Randomized, Double Blind, Placebocontrolled Study to Reduce Incidence of Pre-dialysis Hyperkalemia With Sodium Zirconium Cyclosilicate (DIALIZE)

Last checked: Nov 20, 2026Latest source record: Feb 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 196 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

196

Actual

Start

Dec 14, 2017

Primary completion

Nov 7, 2018

Study completion Nov 7, 2018

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy of ZS in the treatment of hyperkalemia in patients on hemodialysis.

Conditions

  • Hyperkalemia

Interventions

  • PlaceboDrug

    Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) . Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.

  • Sodium Zirconium Cyclosilicate (ZS)Drug

    Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) . Single dose contains from 1 to 3 sachets of ZS 5g depending on dose level assigned to a patient per non-dialysis days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of RespondersTime frame: Evaluation period runs over the last 4 weeks of the treatment period up to 8 weeks, starting after visit 11 and ending on visit 15, thus it comprises post-long inter-dialytic interval visits 12, 13, 14 and 15.
  2. Percentage of Responders When Accounting for Missing Central Laboratory Serum Potassium DataTime frame: Evaluation period runs over the last 4 weeks of the treatment period up to 8 weeks, starting after visit 11 and ending on visit 15, thus it comprises post-long inter-dialytic interval visits 12, 13, 14 and 15.

Locations

53 sites in 4 countries. Site status is shown where the registry gives one.

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Ontario, California

  • Research Site

    San Dimas, California

  • Research Site

    Whittier, California

  • Research Site

    Kansas City, Missouri

  • Research Site

    St Louis, Missouri

  • Research Site

    Paterson, New Jersey

  • Research Site

    Fresh Meadows, New York

  • Research Site

    Great Neck, New York

  • Research Site

    Ridgewood, New York

  • Research Site

    The Bronx, New York

  • Research Site

    East Providence, Rhode Island

  • Research Site

    El Paso, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Hamamatsu, Japan

  • Research Site

    Kumamoto, Japan

  • Research Site

    Miyagi-gun, Japan

  • Research Site

    Nagano, Japan

  • Research Site

    Niigata, Japan

  • Research Site

    Ora-gun, Japan

  • Research Site

    Osaka, Japan

  • Research Site

    Sakaishi, Japan

  • Research Site

    Sashima-gun, Japan

  • Research Site

    Sendai, Japan

  • Research Site

    Shinjuku-ku, Japan

  • Research Site

    Toride-shi, Japan

  • Research Site

    Tsukuba, Japan

  • Research Site

    Wakayama, Japan

  • Research Site

    Yachiyo-shi, Japan

  • Research Site

    Yokosuka-shi, Japan

  • Research Site

    Kemerovo, Russia

  • Research Site

    Kolomna, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Novosibirsk, Russia

  • Research Site

    Omsk, Russia

  • Research Site

    Penza, Russia

  • Research Site

    Podolsk, Russia

  • Research Site

    Rostov-on-Don, Russia

  • Research Site

    Saint Petersburg, Russia

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.